Back to top

A dual effect for reducing fracture risk1-4

Thumbnail

Explore the benefits of EVENITY

This interactive tool helps you get to grips with the EVENITY story, and is guided by an osteoporosis patient who’s on hand to help you discover more.

image
Start
Prescribe EVENITY® first after a fragility fracture in postmenopausal women with severe osteoporosis1
Thumbnail

The first dual-effect, bone-forming biologic

for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture1

Thumbnail

Superior fracture risk reduction

when used for 12 months followed by alendronate vs alendronate alone:

 

  • 8.0% vs 4.1% for new vertebral fractures at 24 months (p<0.001)1,5

  • 13.0% vs 9.7% for clinical fracture (p<0.001), 10.6% vs 8.7% for non-vertebral fracture (p=0.04), and 3.2% vs 2.0% for hip fracture (p=0.02) at primary analysis (median 33 months)1,5

 

Thumbnail

Rapid and superior improvement in BMD

vs alendronate1,5 and teriparatide6 in just 12 months

2-Injections, once-a-month, for 12 months
self administered at home

 

EVENITY provides rapid and superior improvements in BMD1,5 vs alendronate with once-monthly,1 home-delivered dosing, so your patients can continue their treatment without having to leave the house.

contact_rep

Would you like to discuss EVENITY directly with a member of our UCB field team?

EVENITY is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture1

EVENITY is contraindicated in patients with hypersensitivity, hypocalcaemia and history of myocardial infarction or stroke.1

 

One fragility fracture may lead to another7

image

A previous fragility fracture increases
the imminent risk of a subsequent fracture8

From inspiration to innovation

What’s behind EVENITY

From the frontiers of space to the front line of fracture treatment. Watch our short film to discover exactly how EVENITY became reality.

View References
 
  1. EVENITY SmPC.
  2. Cosman F, et al. N Engl J Med 2016;37S:S132-1S43.
  3. Rosen CJ. N Engl J Med 2017:37:71479-1480.
  4. Ferrari SL. Nat Rev Rheumatol 2018;14:128.
  5. Saag K, et al. N Eng J Med 2017;377:1417-1427.
  6. Langdahl BL, et al. Lancet 2017;390:1585-1594.
  7. Toth E, et al. Osteoporos Int 2018 Apr;29(Suppl 1):149-565.
  8. Van Geel TA, et al. Ann Rheum Dis 2009:68:99-102.